The role of cetuximab in pre-treated refractory patients with metastatic colorectal cancer: Outcome study in clinical practice

G. Lelli, S. Cataldo, I. Carandina, B. Urbini, F. Bonetti, M. Marzola, G. Biasco, M. A. Pantaleo, A. Brandes, C. Calandri, E. Ravaioli, O. Nanni, C. Boni, C. Banzi, F. Negri, A. Panetta, F. Di Fabio, D. Turci

Research output: Contribution to journalArticle

Abstract

We carried out a multicentric retrospective study on cetuximab + chemotherapy in pre-treated refractory patients outside clinical protocols, by registering the main clinical and pathological parameters. We evaluated 144 pre-treated patients. Cetuximab was administered usually in combination with irinotecan (93.8%). A 45% disease control rate (complete plus partial responses plus stable disease) was obtained in 55 patients and was related to absence of weight loss (p<0.0001) and high grade (≥2) skin toxicity (p<0.0001). Median time to progression (TTP) was 4 months (95%CI 2.7-5.3) and median overall survival (OS) was 11.8 months (95%CI 8.5-15.1). Performance status ≤1, no weight loss and high grade (≥2) skin toxicity were related both to a longer TTP (p=0.035, p=0.035, p=0.0017) and OS (p<0.0001, p<0.0001, p=0.006). According to multivariate analysis, the absence of weight loss was related to longer TTP (HR 0.331, p=0.004) and OS (HR 0.176, p<0.0001), and EGFR over-expression (3+) to longer TTP (HR 0.402, p=0.020).

Original languageEnglish
Pages (from-to)374-379
Number of pages6
JournalJournal of Chemotherapy
Volume20
Issue number3
Publication statusPublished - Jun 2008

Fingerprint

Colorectal Neoplasms
Outcome Assessment (Health Care)
Weight Loss
irinotecan
Survival
Skin
Clinical Protocols
Multivariate Analysis
Retrospective Studies
Drug Therapy
Cetuximab

Keywords

  • Appropriate prescriptions
  • Clinical outcome
  • Multicenter study
  • Palliative treatment
  • Retrospective study
  • Targeted therapies

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Microbiology (medical)

Cite this

Lelli, G., Cataldo, S., Carandina, I., Urbini, B., Bonetti, F., Marzola, M., ... Turci, D. (2008). The role of cetuximab in pre-treated refractory patients with metastatic colorectal cancer: Outcome study in clinical practice. Journal of Chemotherapy, 20(3), 374-379.

The role of cetuximab in pre-treated refractory patients with metastatic colorectal cancer : Outcome study in clinical practice. / Lelli, G.; Cataldo, S.; Carandina, I.; Urbini, B.; Bonetti, F.; Marzola, M.; Biasco, G.; Pantaleo, M. A.; Brandes, A.; Calandri, C.; Ravaioli, E.; Nanni, O.; Boni, C.; Banzi, C.; Negri, F.; Panetta, A.; Di Fabio, F.; Turci, D.

In: Journal of Chemotherapy, Vol. 20, No. 3, 06.2008, p. 374-379.

Research output: Contribution to journalArticle

Lelli, G, Cataldo, S, Carandina, I, Urbini, B, Bonetti, F, Marzola, M, Biasco, G, Pantaleo, MA, Brandes, A, Calandri, C, Ravaioli, E, Nanni, O, Boni, C, Banzi, C, Negri, F, Panetta, A, Di Fabio, F & Turci, D 2008, 'The role of cetuximab in pre-treated refractory patients with metastatic colorectal cancer: Outcome study in clinical practice', Journal of Chemotherapy, vol. 20, no. 3, pp. 374-379.
Lelli, G. ; Cataldo, S. ; Carandina, I. ; Urbini, B. ; Bonetti, F. ; Marzola, M. ; Biasco, G. ; Pantaleo, M. A. ; Brandes, A. ; Calandri, C. ; Ravaioli, E. ; Nanni, O. ; Boni, C. ; Banzi, C. ; Negri, F. ; Panetta, A. ; Di Fabio, F. ; Turci, D. / The role of cetuximab in pre-treated refractory patients with metastatic colorectal cancer : Outcome study in clinical practice. In: Journal of Chemotherapy. 2008 ; Vol. 20, No. 3. pp. 374-379.
@article{69941693f0ee498689b4a5842ff61ada,
title = "The role of cetuximab in pre-treated refractory patients with metastatic colorectal cancer: Outcome study in clinical practice",
abstract = "We carried out a multicentric retrospective study on cetuximab + chemotherapy in pre-treated refractory patients outside clinical protocols, by registering the main clinical and pathological parameters. We evaluated 144 pre-treated patients. Cetuximab was administered usually in combination with irinotecan (93.8{\%}). A 45{\%} disease control rate (complete plus partial responses plus stable disease) was obtained in 55 patients and was related to absence of weight loss (p<0.0001) and high grade (&ge;2) skin toxicity (p<0.0001). Median time to progression (TTP) was 4 months (95{\%}CI 2.7-5.3) and median overall survival (OS) was 11.8 months (95{\%}CI 8.5-15.1). Performance status &le;1, no weight loss and high grade (&ge;2) skin toxicity were related both to a longer TTP (p=0.035, p=0.035, p=0.0017) and OS (p<0.0001, p<0.0001, p=0.006). According to multivariate analysis, the absence of weight loss was related to longer TTP (HR 0.331, p=0.004) and OS (HR 0.176, p<0.0001), and EGFR over-expression (3+) to longer TTP (HR 0.402, p=0.020).",
keywords = "Appropriate prescriptions, Clinical outcome, Multicenter study, Palliative treatment, Retrospective study, Targeted therapies",
author = "G. Lelli and S. Cataldo and I. Carandina and B. Urbini and F. Bonetti and M. Marzola and G. Biasco and Pantaleo, {M. A.} and A. Brandes and C. Calandri and E. Ravaioli and O. Nanni and C. Boni and C. Banzi and F. Negri and A. Panetta and {Di Fabio}, F. and D. Turci",
year = "2008",
month = "6",
language = "English",
volume = "20",
pages = "374--379",
journal = "Journal of Chemotherapy",
issn = "1120-009X",
publisher = "Maney Publishing",
number = "3",

}

TY - JOUR

T1 - The role of cetuximab in pre-treated refractory patients with metastatic colorectal cancer

T2 - Outcome study in clinical practice

AU - Lelli, G.

AU - Cataldo, S.

AU - Carandina, I.

AU - Urbini, B.

AU - Bonetti, F.

AU - Marzola, M.

AU - Biasco, G.

AU - Pantaleo, M. A.

AU - Brandes, A.

AU - Calandri, C.

AU - Ravaioli, E.

AU - Nanni, O.

AU - Boni, C.

AU - Banzi, C.

AU - Negri, F.

AU - Panetta, A.

AU - Di Fabio, F.

AU - Turci, D.

PY - 2008/6

Y1 - 2008/6

N2 - We carried out a multicentric retrospective study on cetuximab + chemotherapy in pre-treated refractory patients outside clinical protocols, by registering the main clinical and pathological parameters. We evaluated 144 pre-treated patients. Cetuximab was administered usually in combination with irinotecan (93.8%). A 45% disease control rate (complete plus partial responses plus stable disease) was obtained in 55 patients and was related to absence of weight loss (p<0.0001) and high grade (&ge;2) skin toxicity (p<0.0001). Median time to progression (TTP) was 4 months (95%CI 2.7-5.3) and median overall survival (OS) was 11.8 months (95%CI 8.5-15.1). Performance status &le;1, no weight loss and high grade (&ge;2) skin toxicity were related both to a longer TTP (p=0.035, p=0.035, p=0.0017) and OS (p<0.0001, p<0.0001, p=0.006). According to multivariate analysis, the absence of weight loss was related to longer TTP (HR 0.331, p=0.004) and OS (HR 0.176, p<0.0001), and EGFR over-expression (3+) to longer TTP (HR 0.402, p=0.020).

AB - We carried out a multicentric retrospective study on cetuximab + chemotherapy in pre-treated refractory patients outside clinical protocols, by registering the main clinical and pathological parameters. We evaluated 144 pre-treated patients. Cetuximab was administered usually in combination with irinotecan (93.8%). A 45% disease control rate (complete plus partial responses plus stable disease) was obtained in 55 patients and was related to absence of weight loss (p<0.0001) and high grade (&ge;2) skin toxicity (p<0.0001). Median time to progression (TTP) was 4 months (95%CI 2.7-5.3) and median overall survival (OS) was 11.8 months (95%CI 8.5-15.1). Performance status &le;1, no weight loss and high grade (&ge;2) skin toxicity were related both to a longer TTP (p=0.035, p=0.035, p=0.0017) and OS (p<0.0001, p<0.0001, p=0.006). According to multivariate analysis, the absence of weight loss was related to longer TTP (HR 0.331, p=0.004) and OS (HR 0.176, p<0.0001), and EGFR over-expression (3+) to longer TTP (HR 0.402, p=0.020).

KW - Appropriate prescriptions

KW - Clinical outcome

KW - Multicenter study

KW - Palliative treatment

KW - Retrospective study

KW - Targeted therapies

UR - http://www.scopus.com/inward/record.url?scp=47349115226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47349115226&partnerID=8YFLogxK

M3 - Article

C2 - 18606595

AN - SCOPUS:47349115226

VL - 20

SP - 374

EP - 379

JO - Journal of Chemotherapy

JF - Journal of Chemotherapy

SN - 1120-009X

IS - 3

ER -